Vaxelis Approved to Prevent Six Infectious Diseases in Children
December 21, 2018 – The U.S. FDA has approved Vaxelis™ [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine], a pediatric hexavalent combination vaccine manufactured by Sanofi and Merck. Vaxelis is indicated to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.
Vaxelis protects against six of the 14 diseases included in the United States’ recommended vaccination schedule for children, allowing healthcare providers to minimize the number of injections required to complete a childhood vaccination series. Vaxelis should be given as a three-dose series of 0.5mL intramuscular injections. Children should also receive a fourth dose of a pertussis (whooping cough) vaccine as part of their vaccination schedule. Immunization with Vaxelis can begin as early as six weeks of age, and the series should be completed before the child’s fifth birthday.
Sanofi and Merck plan to launch the vaccine in 2020. Pricing information is not yet available.